Connect with us

News

US medtech company raises US$25m to drive innovation in women’s healthcare

The company’s first product is currently undergoing clinical investigation

Published

on

The US medtech company Rejoni has closed a US$25m Series B funding round to accelerate innovation women’s healthcare.

Rejoni, a privately held medtech company based in Massachusetts, is developing gynaecological products with the aim to improve women’s healthcare.

Its first product, Juveena Hydrogel System (HS), is currently undergoing clinical investigation under an IDE pivotal study in the US.

The Juveena HS is being developed for use as a temporary implant to prevent the intrauterine adhesions (IUA) that can form inside the uterine cavity following transcervical gynaecological procedures.

The proceeds from the new round, led by Catalyst Health Ventures, with support from Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures and Iyengar Capital Partners, will be used to complete the study and explore additional therapeutic indications in women’s health.

“We recently began enrolling our first patients in the Juveena HS pivotal study and this capital will allow us to complete the study and to build a robust pipeline of differentiated and innovative products,” said Amar Sawhney, CEO of Rejoni.

“We welcome the support of our new and existing investors and look forward to bringing Juveena and other much-needed therapies to the gynaecological community.”

Darshana Zaveri, founder and managing partner at Catalyst Health Ventures, who will also be joining Rejoni’s board of directors, added: “The women’s health market is in severe need for innovative therapies and has been underserved for too long.

“We are excited to support the experienced, talented team at Rejoni in developing a remarkable portfolio of products addressing major unmet needs in gynaecological surgery.”

Pregnancy

Wales becomes first UK nation to unite maternity care under a single digital record

Published

on

System C has completed the national rollout of BadgerNet Maternity across all seven NHS Health Boards in Wales. This is the first time any UK nation has unified its maternity care under a single digital record and patient-facing app.

With approximately 26,000 babies born annually in Wales, BadgerNet connects maternity information across organisational boundaries in the country.

Expectant parents can access their records, maternity appointments and key updates digitally through a single app, wherever they receive care while clinicians have secure access to the right information at the point of care.

The national three-year agreement across all Heath Boards replaces a patchwork of separate local systems and eliminates the need for paper hand-held notes.

Anthony Tracey is director of digital at Hywel Dda University Health Board, the final of the Welsh Health Boards to go live with BadgerNet.

He said: “The rollout of BadgerNet across Wales is a vitally important step forward in modernising our maternity services and providing a consistent service across the country.

“By giving expectant parents direct access to their information and enabling clinicians to share data more effectively, we are strengthening safety, transparency and consistency in maternity care nationwide.”

For expectant parents, the single digital maternity record transforms how they engage with their care.

Instead of carrying paper notes and repeating information at every appointment, parents can access key details, appointments and updates digitally, supporting more informed conversations and shared decision-making.

The result is greater transparency, fewer administrative frustrations and a more joined-up experience throughout pregnancy and into the postnatal period, regardless of which health board they fall under.

For clinicians and Health Boards, the joined-up approach reduces duplication and streamlines handovers across teams and sites. Information is digitally captured once and made available securely wherever it is needed, helping to minimise errors, reduce time spent tracking down notes and support more efficient multidisciplinary working.

At a national level, linking maternity data across Wales creates a foundation for safer, more consistent care.

Aggregated, standardised information enables earlier identification of trends and variation, supports evidence-based policy decisions and enhances long-term service planning.

With a comprehensive view of maternity activity and outcomes across the country, Wales is now better positioned to raise standards for parents, babies and families.

Guy Lucchi, managing director of healthcare at System C, added: “Delivering a truly national approach across all seven Health Boards is a significant achievement for Wales.

“One shared system means information flows with the patient, not the organisation.

“That reduces duplication, supports earlier identification of risk and frees up valuable clinical time.

“Crucially, linking maternity data at a national level provides powerful insight to drive improvement. Health Boards can benchmark, plan services with greater confidence and ensure resources are targeted where they are needed most, while expectant parents benefit from clearer communication and a more connected experience of care.”

Continue Reading

Menopause

Perimenopause misinformation ‘putting women at risk’

Published

on

Perimenopause misinformation on social media is putting women at risk of unintended pregnancies, unnecessary medication and missed diagnoses, experts have said.

Awareness of menopause and treatments such as hormone replacement therapy, or HRT, has been raised by efforts including a prominent documentary by Davina McCall.

But as a growing number of women encounter misleading information on social media, there are concerns that some could be led to false conclusions that can obscure real underlying health difficulties.

“Everyone thinks they’re menopausal,” said Dr Paula Briggs, a consultant in sexual and reproductive health.

“So we are seeing younger and younger women asking for HRT when what they need is hormonal contraception, as they’re still fertile.

“I work in an abortion service and we’re seeing more women over 35 now who believe themselves to be menopausal and are gobsmacked when they become pregnant.”

According to the British Menopause Society, more than 80 per cent of women will be menopausal by the age of 54, meaning they have not had a period for 12 months or more, with about 5 per cent reaching menopause before the age of 45.

But menopause is not a sudden stop. Instead, women go through a transition known as perimenopause over months or years.

During this time, hormone levels fluctuate and can cause symptoms such as changes in menstrual patterns, hot flushes and difficulty sleeping.

Briggs said misinformation around perimenopause is concerning.

“I look at things like Instagram to see what they are exposed to and I am horrified,” she said, citing examples of women in their 30s being told to demand HRT if they are unable to sleep or are struggling with migraines, and to switch GPs if denied.

Or women being told they should seek testosterone treatment.

“I’m not anti any of these things in the right person, but females produce their own testosterone lifelong, even women without ovaries, so the idea that everybody has to demand testosterone is bonkers,” Briggs said.

Dr Channa Jayasena, an expert in reproductive endocrinology at Imperial College London, also raised concerns.

“It’s great that there’s better [public] awareness [about perimenopause]. And I think many doctors are completely unaware about how debilitating the symptoms of perimenopause can be,” he said.

“But the flipside of that, I think there’s a risk that some women are being mislabelled as having perimenopause when they have other things that are wrong.”

Prof Janice Rymer, chair of the British Menopause Society, agreed.

“[If you are] having regular periods naturally, then you’re not perimenopausal, end of story. You’ve got good hormone levels,” she said.

Rymer added that there is a perception that any symptom affecting women between the ages of 40 and 60 is due to perimenopause or menopause and that HRT is required.

“I think HRT is completely wonderful,” Rymer said. But, she added, “it’s not for women who don’t need it,” noting that in such situations it can cause heavy bleeding.

Briggs said a key concern arising from misinformation around perimenopause is that women are stopping contraception, thinking it is no longer needed.

Jayasena suggested that could be because of messaging around how fertility declines with age.

“I think we’ve got a real awareness about the timelines for optimum fertility and optimum response for IVF. IVF stops working well beyond the age of 42. It’s easy to translate that to an assumption that you can’t get pregnant naturally, when actually you can,” he said.

Experts have also raised concerns over a pushback against hormonal contraception, something that is particularly acute among younger women, even though demand for HRT is growing.

While they stress contraception is not a one-size-fits-all issue, Briggs noted there are many progestogen-only contraceptives, which use a synthetic version of the hormone progesterone, that can be used alongside HRT to protect against pregnancy while managing symptoms associated with perimenopause.

In addition, she said, there are modern forms of the combined pill that are safer for use in women experiencing perimenopause than traditional combined pills, as they contain a natural form of oestrogen.

Essentially, said Jayasena, “it’s a mini pill plus a bit of HRT.”

Dr Zara Haider, president of the College of Sexual and Reproductive Healthcare, said misinformation is a significant issue, particularly around fertility and hormone use.

She said: “We still see women stopping contraception too early because they assume they can’t get pregnant, when in reality contraception is needed until menopause is confirmed or until age 55.

“There’s also been a lasting impact from outdated or flawed studies around risks like breast cancer, which has understandably made some women cautious about hormones.

“At the same time, it’s positive that public conversations, including high-profile campaigns, have helped bring menopause into the mainstream.

“The challenge now is making sure women are getting accurate, evidence-based information to make informed decisions.”

Continue Reading

Insight

Early PET scan could chemo response in aggressive breast cancer – study

Published

on

An early PET scan after one cycle of chemotherapy may help predict how aggressive breast cancer responds to treatment, a study suggests.

Research led by The Institute of Cancer Research, London and King’s College London suggests that an early scan taken after one cycle of chemotherapy could help predict how well a patient’s cancer will respond to treatment.

The study focused on patients with triple-negative breast cancer (TNBC), an aggressive form of the disease in which cancer cells lack receptors for the hormones oestrogen and progesterone, as well as the HER2 protein.

Patients with TNBC are usually treated with chemotherapy prior to surgery. While many respond well, residual disease at surgery, typically around six months later, is associated with a significantly poorer prognosis. Identifying people sooner who are unlikely to respond remains a major clinical challenge.

The research explored whether using PET imaging shortly after treatment begins, rather than relying only on MRI scans later in the treatment process, could provide earlier insight into how a patient’s cancer is responding. Twenty-two patients were recruited, with fourteen undergoing FDG-PET scans before treatment and after the first cycle of chemotherapy.

The findings, published in Clinical Cancer Research, showed that changes seen on PET scans after just one cycle of chemotherapy were strongly associated with subsequent response, including whether there was no detectable cancer, known as a complete response, by the end of treatment. Importantly, early PET response showed stronger associations with treatment outcomes than standard mid-treatment MRI scans in this study.

Being able to identify patients who are not responding well at an early stage could allow clinicians to adjust treatment sooner or consider alternative approaches. These findings may also support future strategies to better tailor treatment intensity to individual patients.

The study also compared two types of PET tracers, FDG and FLT, to determine which was most suitable. While both met the study’s technical criteria, FDG-PET was selected for further evaluation due to its better image quality, greater consistency and wider use in clinical practice.

The research also explored how imaging changes after just one cycle of chemotherapy relate to the body’s immune response to treatment. Biopsies taken before and after the first cycle of chemotherapy showed that an increase in immune cells within the tumour was strongly associated with both early PET changes and improved treatment outcomes.

The researchers emphasise that these findings now need to be validated in larger studies. Future work will aim to confirm these results in broader patient groups and explore more accessible imaging approaches, such as ultrasound, alongside PET and MRI.

Sheeba Irshad, professor of cancer immunology at King’s College London and lead of the Breast Cancer Now KCL Research Unit, said:

“In patients who had PET scans both before treatment and after the first cycle, we found that this early scan could predict whether they were likely to achieve a complete response by the end of treatment. These findings highlight the potential of early imaging to guide treatment decisions, and now need to be validated in larger, modern clinical trials.”

Andrew Tutt, professor of breast oncology at The Institute of Cancer Research, London, said:

“Research that helps us determine early who is already benefitting from standard neoadjuvant chemotherapy and who might benefit from clinical trials to find better treatments is vital. This study shows that FDG-PET may have great value in this regard. We hope to be able to design studies that further investigate and validate these findings.”

The study was supported by funding from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, Breast Cancer Now, Cancer Research UK, and Guy’s and St Thomas’ Charity.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.